"Subtle signs of joint involvement detectable using magnetic resonance imaging (MRI) of the hand helped identify a subset of patients with psoriasis who were at high risk of developing psoriatic arthritis (PsA), researchers report in an article pu"...
DOSAGE AND ADMINISTRATION
Bottle: Instruct patients to shake bottle prior to using Taclonex® Topical Suspension and to wash their hands after applying the product.
Applicator: Instruct patients to wash their hands if they get Taclonex® Topical Suspension on their fingers.
Apply Taclonex® Topical Suspension to affected areas once daily for up to 8 weeks. Therapy should be discontinued when control is achieved.
Patients 18 years and older should not use more than 100 g per week and patients 12 to 17 years should not use more than 60 g per week.
Taclonex® Topical Suspension should not be used with occlusive dressings unless directed by a physician. Taclonex® Topical Suspension is not for oral, ophthalmic, or intravaginal use. Avoid use on the face, groin, or axillae, or if skin atrophy is present at the treatment site.
Dosage Forms And Strengths
Topical Suspension, 0.005%/0.064%
Each gram of Taclonex® Topical Suspension contains 52.18 mcg of calcipotriene hydrate (equivalent to 50 mcg of calcipotriene) and 0.643 mg of betamethasone dipropionate (equivalent to 0.5 mg of betamethasone). Taclonex® Topical Suspension is a viscous, nearly odorless, almost clear, colorless to slightly off-white suspension.
Applicator: After priming, each full actuation delivers a consistent amount of Taclonex® Topical Suspension.
Storage And Handling
Taclonex® Topical Suspension is a viscous, nearly odorless, almost clear, colorless to slightly off-white suspension. It is available as: 60 g bottle (NDC 50222-501-06)
60 g cartridge with applicator (NDC 50222-499-60)
120 g (2 bottles of 60 g) (NDC 50222-501-66)
Store between 20°C-25°C (68°F-77°F); excursions permitted between 15°C-30°C (59°F-86°F). [See USP controlled room temperature.]
Do not refrigerate.
Bottle: Keep the bottle in the outer carton when not in use. Unused product should be discarded six months after the bottle has been opened.
Applicator: Unused product should be discarded six months after the cartridge has been opened.
Bottle: Shake before use. Applicator: Follow the enclosed “Instructions for Use”. Keep out of reach of children
Manufactured by: LEO Laboratories Ltd., 285 Cashel Road, Dublin 12, Ireland Distributed by: LEO Pharma Inc., 1 Sylvan Way, Parsippany, NJ 07054. Revised: June 2016This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 7/6/2016
Additional Taclonex Scalp Information
Taclonex Scalp - User Reviews
Taclonex Scalp User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.